Comparative Pharmacology
Head-to-head clinical analysis: CEFMAX versus CEFOBID IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFMAX versus CEFOBID IN PLASTIC CONTAINER.
CEFMAX vs CEFOBID IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CEFMAX (cefepime) is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria and PBP-1a/1b in Gram-positive bacteria, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It has zwitterionic properties facilitating rapid penetration through Gram-negative outer membranes and is relatively resistant to hydrolysis by many beta-lactamases, including AmpC beta-lactamases.
Cefoperazone, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
2 g IV every 8-12 hours; usual total daily dose 4-6 g, severe infections up to 12 g daily divided q8h.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <10 mL/min).
2.2 hours (normal renal function); prolonged to 4-5 hours in elderly or hepatic impairment; in severe renal failure (CrCl <10 mL/min), may extend up to 8 hours.
Primarily renal (80–90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <5%.
Renal: 65-85% unchanged; biliary: 10-20% (fecal elimination); total renal clearance approximates glomerular filtration rate.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic